Latest: FDA Approves New Biosimilar for Oncology Treatment

AAIC Presentation Highlights Improved Efficacy and Safety With Lecanemab Subcutaneous Autoinjector

0 Mins
New findings reveal the promising efficacy and safety of a subcutaneous lecanemab autoinjector for early Alzheimer disease treatment, enhancing patient care.
Tags:
📢

Advertisement

300x250 Banner

Recent Content

COPD Biologics: Early Treatment Insights

Pulmonology • 2 hours ago

Antihypertensive Medication Guidelines

Cardiology • 4 hours ago

Juvenile Arthritis Care Transition

Rheumatology • 6 hours ago